We use privacy-friendly, cookieless analytics (Plausible) plus one first-party cookie for anonymous visit counting — no advertising and no cross-site tracking. See our Cookie Policy and Privacy Policy.
Federal IDR · Code overview
Out of network Facet joint injection, cervical, second level, CPT 64491
The denial, the code, and the path to recovery.
Out of network Facet joint injection, cervical, second level (CPT 64491) is routinely paid below the billed charge or denied outright. Most practices treat what arrives as the amount owed. Under the No Surprises Act it is an opening offer, and federal independent dispute resolution exists to contest it. We prepare the submission, and we can file it for you.
- Code
- CPT 64491 (add-on)
- Body region
- cervical/thoracic spine
- Typical setting
- ASC or office
Add-on injection of a second cervical or thoracic facet joint level.
Why Facet joint injection, cervical, second level gets paid short out of network
Anchored to the qualifying payment amount (QPA)
The plan pays Facet joint injection, cervical, second level at its own qualifying payment amount — its median in-network rate for the area — and treats that as the answer. Under the No Surprises Act the QPA is the plan's opening anchor, not a cap, and certified IDR entities weigh several other factors against it.
Out-of-network reduction with no contract on file
With no negotiated rate for Facet joint injection, cervical, second level (CPT 64491), the allowed amount is reduced to an out-of-network schedule that rarely reflects what the cervical/thoracic spine procedure actually involves in a ASC or office setting.
Down-coding or documentation holds
Facet joint injection, cervical, second level claims are frequently held or down-coded pending operative notes, then paid short once submitted — a gap federal IDR is designed to contest with the right clinical record attached.
Add-on underpayment compounds per level
CPT 64491 is an add-on billed alongside a primary procedure. Underpayment stacks with every additional level, so the recoverable gap grows across a multi-level case.
The federal pathway to recovery
There is a defined federal pathway between a payer's underpayment and a binding arbitrated amount: an open negotiation window, an eligibility determination, a batching decision, then arbitration. Each step has a hard deadline, and missing one forfeits the claim. Sydra screens eligibility, assembles the evidence and offer, files, and tracks every deadline so a Facet joint injection, cervical, second level claim never lapses by default.
Providers win roughly 88% of IDR determinations they contest. Sydra is a flat, predictable fee — less than half of what most contingency firms charge. We file it, you keep the recovery.
Facet joint injection, cervical, second level (CPT 64491) — common questions
Can out-of-network Facet joint injection, cervical, second level (CPT 64491) claims go through federal IDR?
Yes. If the item or service qualifies under the No Surprises Act and open negotiation has passed without resolution, either party can initiate independent dispute resolution to contest the payment on CPT 64491.
Why is Facet joint injection, cervical, second level underpaid out of network?
Per-level facet add-on. Insurers anchor to the qualifying payment amount and apply out-of-network reductions, which is exactly what federal IDR exists to contest.
What does Sydra do with a Facet joint injection, cervical, second level denial?
Sydra checks whether the Facet joint injection, cervical, second level claim qualifies, assembles a compliant IDR submission with the supporting evidence and your offer, tracks every deadline, and can file it for you — for a flat fee, never a percentage of the recovery.
Browse all Interventional pain codes, or return to the Federal IDR hub.
Facet joint injection, cervical, second level denials by state
No outcome is guaranteed. Results vary by claim, payer, specialty, and documentation. Any general figures reflect the published federal record across all disputes, not a prediction about your claim. This is general information, not legal or financial advice.
Medically & clinically reviewed by Dr. John M. Abrahams, MD
Board-certified neurosurgeon and founder of Sydra · Last reviewed September 2026 · About the author
Sources
Figures reflect the published federal record across all disputes, not a prediction about any individual claim. This is general information, not legal or financial advice.